Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 16/20 | 0.64 |
| ▸ | FLT1 | P17948 | 8/20 | 0.64 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.64 |
| ▸ | FLT4 | P35916 | 2/20 | 0.64 |
| ▸ | EPHB2 | P29323 | 1/20 | 0.64 |
| ▸ | RET | P07949 | 2/20 | 0.63 |
| ▸ | KIF5B | P33176 | 2/20 | 0.63 |
| ▸ | EGFR | P00533 | 6/20 | 0.62 |
| ▸ | EPHA2 | P29317 | 9/20 | 0.61 |
| ▸ | EPHB4 | P54760 | 8/20 | 0.61 |
| ▸ | ERBB2 | P04626 | 6/20 | 0.61 |
| ▸ | SRC | P12931 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30792543 | 0.91 | EGFR (0.66) | KDRFLT1FGFR1FLT4EPHB2 | |
| SCHEMBL21541684 | 0.91 | EGFR (0.66) | KDRFLT1FGFR1FLT4EPHB2 | |
| SCHEMBL6669352 | 0.91 | KDR (0.77) | KDRFLT1FGFR1FLT4EPHB2 | |
| SCHEMBL20354973 | 0.90 | KDR (0.63) | KDRFLT1FGFR1FLT4EPHB2 | |
| SCHEMBL20355393 | 0.88 | KDR (0.64) | KDRFLT1FGFR1FLT4EPHB2 | |
| SCHEMBL21557447 | 0.88 | KDR (0.83) | KDRFLT1FGFR1FLT4EPHB2 | |
| SCHEMBL21557366 | 0.87 | KDR (0.83) | KDRFLT1FGFR1FLT4EPHB2 | |
| SCHEMBL159404 | 0.87 | KDR (0.64) | KDRFLT1FGFR1FLT4EPHB2 | |
| SCHEMBL17179538 | 0.87 | EGFR (0.70) | KDRFLT1FGFR1FLT4EPHB2 | |
| Hydrochloric Acid SCHEMBL28028749 | 0.86 | KDR (0.63) | KDRFLT1FGFR1FLT4EPHB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3567030-B1 | QUINAZOLINE COMPOUND FOR EGFR INHIBITION | MEDSHINE DISCOVERY INC (CN) | 2022-02-09 | — | — | EP | disclosed |
| EP-3567030-B1 | QUINAZOLINE COMPOUND FOR EGFR INHIBITION | MEDSHINE DISCOVERY INC (CN) | 2022-02-09 | — | — | EP | disclosed |
| US-11040984-B2 | Quinazoline compound for EGFR inhibition | MEDSHINE DISCOVERY INC. (CN) | 2021-06-22 | — | — | US | disclosed |
| US-11040984-B2 | Quinazoline compound for EGFR inhibition | MEDSHINE DISCOVERY INC. (CN) | 2021-06-22 | — | — | US | disclosed |
| US-20200190107-A1 | QUINAZOLINE COMPOUND FOR EGFR INHIBITION | MEDSHINE DISCOVERY INC. (CN) | 2020-06-18 | — | — | US | disclosed |
| US-20200190107-A1 | QUINAZOLINE COMPOUND FOR EGFR INHIBITION | MEDSHINE DISCOVERY INC. (CN) | 2020-06-18 | — | — | US | disclosed |
| EP-3567030-A1 | QUINAZOLINE COMPOUND FOR EGFR INHIBITION | Medshine Discovery Inc. (CN) | 2019-11-13 | — | — | EP | disclosed |
| EP-3567030-A1 | QUINAZOLINE COMPOUND FOR EGFR INHIBITION | Medshine Discovery Inc. (CN) | 2019-11-13 | — | — | EP | disclosed |
| WO-2018121758-A1 | QUINAZOLINE COMPOUND FOR EGFR INHIBITION | 南京明德新药研发股份有限公司 | 2018-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11040984-B2 | Quinazoline compound for EGFR inhibition | EGFR, ERBB2, ERBB4 | KDR 132/4885FLT1 366/4885FGFR1 111/4885 |
| US-20200190107-A1 | QUINAZOLINE COMPOUND FOR EGFR INHIBITION | EGFR, ERBB2, ERBB4 | KDR 132/4885FLT1 366/4885FGFR1 111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.